Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Depreciation and Amortization

Last Annual Value

6.46M

3-Year CAGR

24%

5-Year CAGR

22%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Depreciation and Amortization

NAUT · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.46M
4.3%17.9%N/A 
8.85M
0.6%24.5%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
49.00K
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
5.33M
-11.6%-8.4%N/A
3.02M
0.8%20.5%47.8%
0.00
N/AN/AN/A
698.89K
25.7%34.5%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
13.34M
-0.6%14.5%10.4%
228.00K
-3.3%19.6%N/A
16.25K
10.5%N/AN/A
71.27K
-26.2%-28.5%15.6%
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58